Key Developments: Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

3,275JPY
21 Nov 2014
Price Change (% chg)

¥-25 (-0.76%)
Prev Close
¥3,300
Open
¥3,285
Day's High
¥3,300
Day's Low
¥3,250
Volume
964,400
Avg. Vol
1,542,939
52-wk High
¥4,015
52-wk Low
¥2,107

Search Stocks

Latest Key Developments (Source: Significant Developments)

R&I affirms Chugai Pharmaceutical Co Ltd's rating at "AA-" and announces stable outlook
Wednesday, 1 Oct 2014 02:00am EDT 

Chugai Pharmaceutical Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-".Rating outlook stable.  Full Article

Zeltia SA's PharmaMar and Chugai Pharmaceutical Co Ltd's Chugai Pharma Marketing sign license agreement for Aplidin
Monday, 14 Jul 2014 05:31am EDT 

Zeltia SA:Says its subsidiary, PharmaMar SA, and Chugai Pharma Marketing Ltd, subsidiary of Chugai Pharmaceutical Co Ltd, signed license agreement.Under term of agreement, Chugai Pharma Marketing to market Aplidin in eight european countries (France, Germany, UK, Benelux, Ireland and Austria).Aplidin is PharmaMar product for treatment of multiple myeloma.PharmaMar to receive initial payment of 5 million euros and additional payments are also considered and could reach total number of more than 30 million euros.  Full Article

Chiome Bioscience Inc announces extension of co-research agreement with Chugai Pharmaceutical Co Ltd
Tuesday, 24 Dec 2013 01:00am EST 

Chiome Bioscience Inc and Chugai Pharmaceutical Co Ltd:Says the two companies have decided on extension of co-research agreement, to Dec. 31, 2014.  Full Article

Chugai Pharmaceutical Co Ltd's Anti-Cancer Agent "Avastin" Obtains Approval for Additional Indication and Dosage and Administration of Malignant Glioma-Yakuji Nippo
Friday, 14 Jun 2013 08:00pm EDT 

Yakuji Nippo reported that Chugai Pharmaceutical Co Ltd has obtained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on June 14, 2013, for the additional indication and dosage and administration of "Malignant glioma" for the anti-cancer agent/anti-VEGF humanized monoclonal antibody, "AVASTIN I.V. Infusion 100mg/4mL and 400mg/16mL" (generic name: bevacizumab (recombinant) for Infusion).  Full Article

Chugai Pharmaceutical Co Ltd's Anti-Cancer Agent "Tarceva" Obtains Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations-Yakuji Nippo
Friday, 14 Jun 2013 08:00pm EDT 

Yakuji Nippo reported that Chugai Pharmaceutical Co Ltd has obtained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on June 14, 2013, for the additional indication of "chemotherapy-naive, unresectable, recurrent/advanced non-small cell lung cancer (NSCLC) with EGFR mutations" for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, "Tarceva Tablet 25mg, 100mg and 150mg" (generic name: erlotinib hydrochloride).  Full Article

Chugai Pharmaceutical Co Ltd's Anti-Cancer Agent, Herceptin Obtains Approval for Dosage and Administration for Postoperative Adjuvant Chemotherapy in Breast Cancer-Yakuji Nippo
Friday, 14 Jun 2013 08:00pm EDT 

Yakuji Nippo reported that Chugai Pharmaceutical Co Ltd has obtained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on June 14, 2013, for the additional dosage and administration of "once a week administration for postoperative adjuvant chemotherapy in breast cancer that over expresses HER2" for the anti-cancer agent trastuzumab (genetical recombination (brand name: Herceptin Injection 60 and 150).  Full Article

Chugai Pharmaceutical Co Ltd Files Lawsuit
Tuesday, 19 Feb 2013 01:00am EST 

Chugai Pharmaceutical Co Ltd announced that it has filed a lawsuit against Iwaki Seiyaku Co.,Ltd., TAKATA SEIYAKU Co., Ltd., POLA-Pharma and Japan DKSH, to the Tokyo District Court, for the violation of patent of the keratosis medicine developed by the Company.  Full Article

Chugai Pharmaceutical Co Ltd and Debiopharm Group Announce Exclusive License Agreement for Anti-Cancer Agent, FF284
Tuesday, 8 Jan 2013 01:00am EST 

Chugai Pharmaceutical Co Ltd and Debiopharm Group announced today that on December 17, 2012 , they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology. Under this license agreement, Chugai will grant Debiopharm an exclusive license to develop and commercialise FF284 (Debio 1347) in all countries worldwide including Japan . Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284 (Debio 1347). According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study. In return for the license, Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.  Full Article

Chiome Bioscience Inc Extends Contract Period with Chugai Pharmaceutical Co Ltd
Monday, 7 Jan 2013 01:00am EST 

Chiome Bioscience Inc announced that it has decided to extend the period of a collaboration contract, which was signed with Chugai Pharmaceutical Co Ltd on November 1, 2008, for one year, until December 31, 2013.  Full Article

REFILE-TABLE-Chugai Pharm -9-MTH group results (IFRS)

(Adds company forecast) Oct 24 - Chugai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Sep 30, 2014 Sep 30, 2013 Dec 31, 2014 LATEST YEAR-AGO COMPANY RESULTS RESULT FORECAST Sales 333.43 306

Search Stocks